We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Frontage Expands Clinical Operations in Secaucus, NJ
News

Frontage Expands Clinical Operations in Secaucus, NJ

Frontage Expands Clinical Operations in Secaucus, NJ
News

Frontage Expands Clinical Operations in Secaucus, NJ

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Frontage Expands Clinical Operations in Secaucus, NJ"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Frontage has announced the opening of its newest facility in Secaucus, NJ to expand its clinical research portfolio of services.

As part of Frontage’s strategic growth plans to broaden clinical service capabilities and increase capacity, the company has completed construction of its new 36,000-square-foot 160-bed clinical research center in Secaucus, NJ.

The location of the new facility complements the existing center in nearby Hackensack. The Secaucus facility will include the ability to conduct a wider range of clinical studies including multiple concurrent studies and Phase II-IV studies involving patient populations. This expansion will nearly triple the company’s clinical capacity in the USA.

“We are excited to operate a second facility in New Jersey as it has been an ideal location for our clinical research due to the immediate access to the medical communities as well as subject and patient populations,” said Eileen McAuley, Senior Vice President of Clinical Services.

“Frontage’s ability to provide comprehensive support to our clients and their needs in the early drug development stage is greatly enhanced by our investment in facility expansion and clinical services infrastructure,” said Dr. Song Li, CEO of Frontage.

Advertisement